In vivo, miR-138 treatment potently suppresses glioma growth, decreasing the ratio of intratumoral Treg, reducing the expression of CTLA-4 and PD-1, and leading to a 43% increase in the median survival time [153]. Here, PDCD1 is linked to central nervous system cancer.